Analysis Of The Changes Of Molecular Biology Index Before And After ET Regimen Neoadjuvant Chemotherapy Of Breast Cancer

Objective: Assessed the expression of estrogen receptor(ER), pro- gesterone receptor(PR), human epidermal growth factor receptor 2(Her-2), Ki67 in specimens from breast cancer cases pre- and post-NAC and explore the effect that whether the expression of certain markers changes after NAC using ET regimen in breast cancer.Methods: The 82 cases with primary breast cancer of the Fourth Hospital of Hebei Medical University Breast Center admitted from January 2010 to August 2014. All of the cases had received NAC using paclitaxel in combination with epirubicin. We assessed estrogen receptor(ER), progesterone receptor(PR), human epidermal growth factor receptor 2(Her-2), and Ki67 expression in specimens with coarse needle biopsy before NAC。patients in the implementation of operation treatment After 4 cycles of NAC, We explore the expression in postoperative specimens by the same method. We analyzed the changes of the expression between pre- and post-NAC specimens.Results: Our study found that the expression of 38 patients with Ki67 pre- and post-NAC for breast cancer has changed, which accounted for 80.85%(38/47), The expression of 1 case was enhanced,At the same time, 37 cases were weakened. 20 cases were changed from positive to negative. By statistics that differential expression of Ki67 pre- and post-NAC was statistical significance(P<0.05); The expression of 14 patients with ER pre- and post-NAC for breast cancer has changed, which accounted for 29.79%(14/47), The expression of 5 cases were enhanced,at the same time, 9 cases were weakened. 3 cases were changed from negative to positive, 2 cases were changed from positive to negative. By statistics that differential expression of ER pre- and post-NAC had no statistical significance(P<0.05); The expression of 14 patients with ER pre- and post-NAC for breast cancer had changed, which accounted for 29.79%(14/47), The expression of 5 cases were enhanced,at the same time, 9 cases were weakened. 3 cases were changed from negative to positive, 2 cases were changed from positive to negative. The expression of 17 patients with PR pre- and post-NAC for breast cancer had changed, which accounted for 36.17%(17/47), The expression of 6 cases were enhanced,at the same time,11 cases were weakened. 4 cases were changed from negative to positive, 9 cases were changed from positive to negative. The expression of 9 patients with Her-2 pre- and post-NAC for breast cancer has changed, which accounted for 23.08%(9/39), The expression of 2 cases were enhanced,at the same time,7 cases were weakened. 1 case was changed from negative to positive, 2 cases were changed from positive to negative. The expression of ER,PR,Her-2 had no statistically significant difference in the expression between pre- and post-NAC specimens(P>0.05).Conclusion: Neoadjuvant chemotherapy in breast cancer using ET scheme, the expression of ER, PR, Her-2, Ki67 pre- and post-NAC in part of the cases were changed, but only the changes in the expression of Ki67 pre- and post-NAC had statistical significance(P<0.05); The change is mainly reflected in the high expression before NAC, into the low expression of surgical specimens after chemotherapy, showed that high expression of Ki67 tumor cells more sensitive to chemotherapy, Ki67 is a sensitive index to chemotherapy, has an important guiding significance for predicting the curative effect. The expression of ER、PR、Her-2 and Ki67 had changes before and after NAC, but only the changes of the expression of Ki67 pre- and post-NAC had statistically statistical difference(P<0.05). The changes of ER、PR、He-2 had no statistically statistical difference(P>0.05). ER, PR, Her-2 changes had no statistical significance(P>0.05). But there were expression changes in part of the cases. The changes shows that It is necessary to adjust the treatment plan and scheme; and review the patients which expression changes of Her-2 pre- and post-NAC, or by FISH detection, In order to defined the expression of Her-2, so that to guide the treatment and to determine the risk of recurrence and prognosis.